Phospho-TGF beta Receptor I (Ser165)抗体;Phospho-TGF beta Receptor I (Ser165) Antibody—艾普蒂 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P11132(Map2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P11132(Map2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The Phospho-TGF beta Receptor I (Ser165) antibody is a specialized tool used to detect the activated form of TGF-beta receptor type I (TGFBR1), a key component of the transforming growth factor-beta (TGF-β) signaling pathway. TGF-β receptors are serine/threonine kinases that regulate diverse cellular processes, including proliferation, differentiation, apoptosis, and immune responses. Upon ligand binding, TGFBR1 forms a complex with TGFBR2. leading to phosphorylation of TGFBR1 at specific serine/threonine residues, such as Ser165. This phosphorylation event is critical for propagating downstream signaling via Smad proteins (e.g., Smad2/3), which translocate to the nucleus to modulate gene expression.

The Phospho-TGFBR1 (Ser165) antibody specifically recognizes the phosphorylated Ser165 residue, enabling researchers to study receptor activation dynamics in response to TGF-β stimulation or pathological conditions. It is widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to assess TGF-β pathway activity in cell lines, tissues, or disease models. Dysregulation of TGF-β signaling is implicated in fibrosis, cancer (dual roles in tumor suppression and metastasis), and autoimmune disorders, making this antibody valuable for mechanistic and therapeutic studies. Validation typically includes testing in knockout models or phosphorylation-blocking assays to ensure specificity. Proper controls are essential to distinguish between basal and induced phosphorylation states.